Autolus Therapeutics plc Receives Average Rating of 'Buy' from Analysts

Autolus Therapeutics plc (NASDAQ:AUTL) has received a consensus recommendation of "Buy" from the six brokerages monitoring the company, as reported by Marketbeat Ratings. All six investment analysts rated the stock positively, indicating a generally favorable outlook.

The average price target provided by analysts for Autolus Therapeutics over the next year is $9.52. This forecast reflects the analysts' confidence in the company's potential for growth in the clinical-stage biopharmaceutical sector.

Several research analysts have shared their insights on AUTL shares. For instance, Needham & Company LLC reiterated a "buy" rating and established a target price of $10.00 for Autolus Therapeutics shares in a report released on January 13th. Conversely, Wells Fargo & Company adjusted their price target downward from $8.00 to $6.00 while maintaining an "overweight" rating in a research note published on March 21st.

Recent Trading Activity of Autolus Therapeutics

In the fourth quarter, various institutional investors adjusted their positions in Autolus Therapeutics. Jane Street Group LLC entered a new position in the company, valued at approximately $26,000. Barclays PLC significantly increased its stake by 1,094.3%, now holding 11,859 shares worth around $28,000 after buying an additional 10,866 shares. Capstone Investment Advisors LLC also acquired a new stake valued at $51,000 in the third quarter, while Dumont & Blake Investment Advisors LLC and Arkadios Wealth Advisors made similar investments worth $35,000 and $47,000, respectively. Overall, institutional ownership is significant, with hedge funds and other institutional investors controlling approximately 72.83% of the company's stock.

Performance Overview of Autolus Therapeutics

On its most recent trading day, NASDAQ:AUTL was down 5.3%, opening at $1.62. The stock has seen a low of $1.56 and a high of $6.48 over the past twelve months. Currently, the company boasts a market capitalization of $431.07 million, with a P/E ratio of -1.34 and a beta of 2.07. The 50-day moving average price stands at $2.00 while the two-hundred day moving average is at $2.87.

Autolus Therapeutics recently announced its earnings results on March 20th. The company reported earnings per share (EPS) of ($0.09) for the quarter, exceeding analysts' expectations of ($0.21) by $0.12. However, revenue for the quarter was reported at only $0.03 million, significantly lower than the anticipated $2.98 million. Analysts project that Autolus Therapeutics will report -0.94 earnings per share for the current year.

Company Overview of Autolus Therapeutics

Autolus Therapeutics plc is a clinical-stage biopharmaceutical firm focused on developing T cell therapies for cancer and autoimmune diseases. The company's clinical-stage therapies consist of several investigational treatments including obecabtagene autoleucel (AUTO1), currently in Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL), AUTO1/22 for pediatric patients with relapsed or refractory ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG targeting neuroblastoma, and AUTO8 aimed at treating multiple myeloma.

Autolus, Therapeutics, Stocks